Back to results
US 2010/0249112 A1Published application
Combination of chk and parp inhibitors for the treatment of cancers
AssigneeAstrazeneca R&D
InventorsMark James O'Connor, Graeme Cameron Murray Smith, Sonya Zabludoff
Life of this patent
Estimating the term…
Abstract
A combination, comprising a checkpoint kinase (CHK) inhibitor, or a pharmaceutically acceptable salt thereof, and a poly (ADP-ribose)polymerase (PARP) inhibitor, or a pharmaceutically acceptable salt thereof is described.
Claims10
A combination comprising a checkpoint kinase (CHK) inhibitor, or a pharmaceutically acceptable salt thereof, and a PARP inhibitor, or a pharmaceutically acceptable salt thereof.
-8. (canceled)
Dependencies are inferred from the claim text.